Investors

Strategic Update and Invitation to Learn More

Building a Future Where Allergies Are Cured, Not Just Managed

Sementis advances a therapeutic vaccine approach for allergic disease

Allergic disease is one of the fastest-growing chronic health conditions globally, affecting millions of people and placing a significant burden on patients, families, and healthcare systems. For many, allergy is not a minor inconvenience—it is a daily source of anxiety and risk, ranging from lifestyle-limiting food avoidance to life-threatening anaphylaxis and asthma.

Despite this impact, current treatments largely focus on managing symptoms or reducing risk. There are no approved short-course therapies designed to deliver durable, long-lasting protection by addressing the underlying immune drivers of allergy.

Sementis is seeking to change that.

A new focus on therapeutic vaccines for allergy

Sementis is an Australian biotechnology company developing therapeutic vaccines designed to retrain the immune system in allergic disease. Unlike preventive vaccines, therapeutic vaccines are intended to modify an existing disease process.

Following a strategic review, Sementis has formally focused the company on allergy, with peanut allergy established as the initial lead indication. This represents a deliberate pivot toward a large, growing market with substantial unmet medical need and no curative solutions currently available.

The challenge: managing allergy is not the same as solving it

For many patients, today’s standard of care still relies on

• strict avoidance of allergens,
• emergency medications to treat reactions, and
• long-term or ongoing therapies that require repeated dosing.

While some newer treatments can reduce the severity or likelihood of reactions, most approaches work only while treatment continues. They are not designed to deliver durable immune change once therapy stops.

Sementis’ approach: retraining the immune system

Sementis is developing a therapeutic vaccine approach designed to retrain the immune system so it responds to allergens in a more tolerant way. The ambition is a short-course treatment more akin to a vaccination schedule than chronic therapy. All data to date is preclinical, generated in laboratory and animal models, and further work will be required to determine safety and effectiveness in people.

The SCV platform: a foundation built over more than a decade

Sementis’ programs are built on its proprietary Sementis Copenhagen Vector (SCV) platform, supported by patents, publications, government funding, and independent technical assessments. The platform is designed for scalability and reuse across multiple allergy indications.

Why peanut allergy—and why now?

Peanut allergy was selected as Sementis’ initial focus because it is often lifelong, potentially life-threatening, and associated with significant daily burden. The allergy field is seeing increasing recognition, active investment, and regulatory evolution supporting novel immune-modifying approaches.

Current focus and next steps

Sementis is advancing its lead program toward clinical development readiness, strengthening manufacturing and quality systems, engaging with regulators, and demonstrating platform breadth across other IgE-mediated allergies.

Governance and leadership

Sementis is led by an experienced Board and management team with deep capability across vaccine development, manufacturing, quality, and commercialisation, supported by long-standing Adelaide-based research collaborations.

For sophisticated investors: learn more

Sementis is engaging with sophisticated and professional investors interested in learning more. Further information is available on request:  [email protected]

Eligibility requirements apply.

This information is provided for general information only and does not constitute an offer or invitation to invest.